In colorectal cancer in vitro, treatment of SGC0946 resulted in decreased γH2AX levels, defective HR-mediated DSB repair (Kari et al., 2019); Rectal cancer cells were sensitized to DNA damage-inducing chemotherapy and PARP inhibition following EPZ-5676 treatment (Amé et al., 2004; Liu et al., 2014). Here, PARP1 is linked to colorectal cancer.